Company intelligence / Profile preview

CelestaPro

Ownership: Private
Development stage: Other

Overview

CelestaPro is a South Korean-based online distributor specializing in aesthetic and medical products, including botulinum toxins, hyaluronic acid fillers, and weight loss treatments. The company primarily targets professionals in the beauty and wellness industry, offering products such as Nabota, Saxenda, and various mesotherapy solutions. In November 2025, CelestaPro received a formal warning letter from the U.S. FDA for the illegal marketing and sale of unapproved and misbranded injectable drug products to U.S. consumers. Despite regulatory scrutiny, the company continues to operate as a global supplier of Korean aesthetic brands, emphasizing fast shipping and customer service.

Therapeutic areas: EndocrinologyDermatologyMetabolic Disorders
Modalities: BiologicPeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

CelestaPro Numbing Cream

Unknown

Beyond the preview

Go deeper on CelestaPro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CelestaPro.

Explore the full profile